234082-00-9

Basic information

• Product Name: 14-(tert-Butoxy)-14-oxotetradecanoic acid
• Synonyms: 14-(tert-Butoxy)-14-oxotetradecanoic acid
• CAS NO: 234082-00-9
• Molecular Formula: C₁₈H₃₄O₄
• Molecular Weight: 314.46016
• Mol File: 234082-00-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 51 °C
• Boiling Point: 417.4±18.0 °C(Predicted)
• Appearance: /
• Density: 0.971±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.78±0.10(Predicted)
• CAS DataBase Reference: 14-(tert-Butoxy)-14-oxotetradecanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 14-(tert-Butoxy)-14-oxotetradecanoic acid(234082-00-9)
• EPA Substance Registry System: 14-(tert-Butoxy)-14-oxotetradecanoic acid(234082-00-9)

Safety Data

• Hazardous Substances Data: 234082-00-9(Hazardous Substances Data)

Usage

General Description

14-(tert-Butoxy)-14-oxotetradecanoic acid is a synthetic organic compound with the chemical formula C20H38O3. It is a derivative of tetradecanoic acid, also known as myristic acid, with a tert-butoxy group attached to the 14th carbon and a ketone group at the same position. 14-(tert-Butoxy)-14-oxotetradecanoic acid is used in chemical research and synthesis as a building block for the creation of other molecules. It has potential uses in the pharmaceutical and agricultural industries due to its unique chemical structure and properties. Additionally, it may have applications in the development of new materials and technologies.

Upstream product

• 821-38-5 1,14-tetradecanedioic acid 
• 75-65-0 tert-butyl alcohol 
• 21646-49-1 tetradecanedioyl dichloride 

Downstream Products

• 234081-80-2 13-[(S)-1-Benzyloxycarbonyl-2-((S)-1,2-bis-hexadecylcarbamoyl-ethylcarbamoyl)-ethylcarbamoyl]-tridecanoic acid tert-butyl ester 
• 234081-90-4 13-[(S)-1-Benzyloxycarbonyl-2-((S)-1,2-bis-hexadecylcarbamoyl-ethylcarbamoyl)-ethylcarbamoyl]-tridecanoic acid 
• 17278-74-9 14-hydroxymyristic acid 
• 50515-98-5 14-hydroxytetradecanoic acid methyl ester 

Relevant articles and documents

MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF

The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Trigger lipids inducing pH-dependent liposome fusion

Aspartic acid-derived artificial lipids (ADLs; s indicates the number of the methylene groups, s=2, 4, 6, 8, 10, 12) (Scheme 1) with various carboxyl alkyl chains as head groups are designed and synthesized, which are incorporated into liposome membranes by sonication. Fluorescence resonance energy transfer (FRET) measurements indicate that ADL6, ADL8 and ADL10 have high lipid-mixing ability in the acidic solution. The other ADLs, however, do not induce remarkable liposome fusion at acidic nor neutral pH. The hydrophobicity of the head groups of ADL6, ADL8 and ADL10 is suitable as triggers of membrane fusion.